Multiple Myeloma Hub

During the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK, the Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the long-term outcomes with ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory multiple myeloma (RRMM) in Cohort A of the CARTITUDE-2 trial. In this interview, Mateos discusses the ≥5-year findings from Cohort A of the phase II CARTITUDE-2 trial (NCT04133636), which evaluated a single cilta-cel infusion in patients with RRMM after 1–3 prior lines of therapy who were exposed to a proteasome inhibitor and are lenalidomide-refractory. Mateos reviews long-term remission and survival outcomes, characteristics associated with prolonged disease control, immune correlates of durable response, and long-term safety findings. Mateos also discusses these findings in the context of cilta-cel use in earlier lines of therapy.

During the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK, the Multiple Myeloma Hub spoke with Rakesh Popat, University College Hospital, London, UK. We asked about interim results from Arm D of the UKMRA ProMMise trial in patients with relapsed/refractory multiple myeloma (RRMM). In this interview, Popat discusses interim results from Arm D of the ProMMise trial, which is evaluating a vision-related anamnestic tool (VRAT) to assess ocular symptoms and function, and guide belantamab mafodotin dosing in patients with RRMM receiving belantamab mafodotin + bortezomib + dexamethasone (BVd). Popat reviews interim results from Stage 1, including the correlation between VRAT and ocular assessments, and outlines the planned evaluation of VRAT-guided dosing without mandated ocular examinations in Stage 2. Intended for healthcare professionals. This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

The Multiple Myeloma Hub spoke with Rakesh Popat, UCL Hospitals NHS Foundation Trust, London, UK. We asked how to optimize outpatient delivery of bispecific antibody therapy for multiple myeloma (MM). In this interview, Popat discusses practical strategies to support the outpatient delivery of bispecific antibody therapy, including patient selection, caregiver support, and access to timely medical care if needed. Popat also outlines approaches that could facilitate step-up dosing in the outpatient setting, such as strategies to reduce the risk of cytokine release syndrome (CRS) and the potential use of wearable technology and remote monitoring. Intended for healthcare professionals. This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the management of toxicities associated with bispecific antibody therapy for multiple myeloma (MM) in community practice. In this interview, Mateos discusses practical considerations for the management of adverse events (AEs) associated with bispecific antibodies in MM. Mateos outlines how to recognize and manage cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), as well as strategies to mitigate infection risk. Mateos also discusses the management of skin, nail, and oral toxicities associated with G-protein coupled receptor family C group 5 member D (GPRC5D)-directed bispecific antibodies. Intended for healthcare professionals. This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

The Multiple Myeloma Hub spoke with Shaji Kumar, Mayo Clinic, Rochester, US. We asked about transitioning patients to community-based bispecific antibody therapy. In this interview, Kumar discusses practical considerations for transitioning bispecific antibody therapy to community-based practice in patients with multiple myeloma. Kumar outlines strategies for monitoring and managing treatment-related toxicities, including cytokine release syndrome, neurological toxicities, cytopenias, and infections. Kumar also discusses patient education, supportive care, and the evolving role of less frequent and subcutaneous bispecific antibody administration in facilitating community-based treatment. Intended for healthcare professionals. This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Meral Beksaç, Istinye University Ankara Liv Hospital, Ankara, TR. We asked about the key findings from two subgroup analyses of the phase III DREAMM-8 trial in RRMM. The first analysis explored outcomes among patients who received only one prior LoT, while the second examined outcomes in patients who achieved sustained MRD negativity. This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Binod Dhakal, Medical College of Wisconsin, Milwaukee, US. We asked, What are the latest findings from the phase I CaMMouflage trial evaluating CB-011 in RRMM? This educational resource is independently supported by Caribou Biosciences. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss strategies for managing belantamab mafodotin-associated ocular toxicities in patients with multiple myeloma (MM). The meeting featured a presentation by guest speaker Lisa Leypoldt, University Medical Center Hamburg-Eppendorf, followed by a faculty discussion on the practical challenges of monitoring, managing, and counseling patients receiving belantamab mafodotin-based therapies. During their presentation, Leypoldt reviewed the mechanisms underlying belantamab mafodotin-associated ocular toxicity, highlighting the role of off-target uptake into corneal epithelial cells and the resulting transient visual symptoms. Leypoldt discussed the clinical manifestations of ocular events, including keratopathy, changes in visual acuity, and patient-reported symptoms, before outlining evidence-based approaches to monitoring and management. Leypoldt also reviewed data from the DREAMM-7 (NCT04246047) and DREAMM-8 (NCT04484623) studies, evaluating the role of dose modifications and extended dosing intervals in managing ocular toxicity. The subsequent faculty discussion focused on multidisciplinary care, patient counseling, and practical considerations for integrating ocular toxicity monitoring into routine clinical practice.This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.